NUT Midline Carcinoma Treatment Market Research Report 2023-2024 & 2034: Market Forecast by Treatment, Route of Administration, and End-User Across 5 Regions and 17+ Countries
09 janv. 2025 10h53 HE
|
Research and Markets
Dublin, Jan. 09, 2025 (GLOBE NEWSWIRE) -- The "NUT Midline Carcinoma Treatment Market by Treatment, by Route of Administration, by End-User, and By Region" report has been added to ...
Oncology Based in-Vivo CRO Business Research Report 2024: Global Market to Reach $2.5 Billion by 2030 - Expansion in Drug Discovery, Translational Research, and Toxicology Fuels Growth
09 janv. 2025 04h01 HE
|
Research and Markets
Dublin, Jan. 09, 2025 (GLOBE NEWSWIRE) -- The "Oncology Based in-Vivo CRO - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for...
5. Jubiläum: Die ICPO Foundation gestaltet eine neue Ära der Krebsbehandlung mit Radiotheranostik für Patienten weltweit
12 déc. 2024 04h00 HE
|
ICPO Foundation
Mit der Einführung der "ICPO Academy for Theranostics" und dem Aufbau eines globalen Netzwerks von ICPO-Centern hat sich die Foundation als international führend in der Wissensvermittlung und der...
5th Anniversary: ICPO Foundation is empowering a new era of cancer treatment with Radiotheranostics for patients worldwide
12 déc. 2024 04h00 HE
|
ICPO Foundation
Launching the "ICPO Academy for Theranostics" and creating its global network of ICPO Centers, the foundation has become an international leader in sharing knowledge and shaping standards in its...
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares
05 déc. 2024 16h05 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
Comprehensive Epidemiology Forecast Reveals Significant Insights into Prader-Willi Syndrome Through 2034
02 déc. 2024 04h42 HE
|
Research and Markets
Dublin, Dec. 02, 2024 (GLOBE NEWSWIRE) -- The "Non-Muscle Invasive Bladder Cancer (NMIBC) - Epidemiology Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.Demographics and...
Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024
27 nov. 2024 16h05 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
10 year 8 Major Market Bladder Cancer Epidemiology Forecasts 2023-2033
18 nov. 2024 10h20 HE
|
Research and Markets
Dublin, Nov. 18, 2024 (GLOBE NEWSWIRE) -- The "Bladder Cancer: Epidemiology Forecast to 2033" report has been added to ResearchAndMarkets.com's offering.Bladder cancer (International Classification...
CARGO Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
12 nov. 2024 16h05 HE
|
Cargo Therapeutics, Inc.
CARGO Therapeutics Reports Third Quarter 2024 Financial Results and
Provides Business Update
Revolution Medicines to Participate in Upcoming Investor Conferences
05 nov. 2024 09h00 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...